Euglena Co., Ltd. and Leave a Nest start joint development of antibody test system for new coronavirus infection (COVID-19)

June 15, 2020
Euglena Co., Ltd.
Leave a Nest Co., Ltd.

　Euglena Co., Ltd. (President: Mitsuru Izumo, hereinafter "Euglena") and Leave a Nest Co., Ltd. (CTO: Jyo Inoue, hereinafter "Leave a Nest") are antibodies against the new coronavirus infection (COVID-19). We will start joint development of inspection system.

　The rapid spread of the new coronavirus infection (COVID-19) has changed our lifestyles and has a major impact on our economic activities. With concerns about the arrival of the second wave, the development of highly accurate and rapid inspection systems is an urgent issue. Against this background, Euglena and Leave a Nest have jointly developed a test system to determine whether the test subject has an antibody against SARS-CoV-2, which is the cause of the new coronavirus infection (COVID-19). increase.

　We started the development of a test system under the technical guidance of Professor Yasufumi Murakami of Tokyo University of Science, and confirmed that antibody testing can be performed at a level that can distinguish positive individuals from a test using 203 samples by volunteers who consented to the test. Did. In the future, we will strive to build a more accurate inspection system.

<About Euglena Co., Ltd.>
In 2005, we succeeded in establishing the world's first edible outdoor mass culture technology for the Euglena A company listed on the First Section of the Tokyo Stock Exchange that develops and sells functional foods and cosmetics that utilize the Euglena produced on Ishigaki Island, and conducts research and development for biofuel production. https://euglena.jp

<About Leave a Nest Co., Ltd.>
Based on the philosophy of "realizing the development of science and technology and contributing to the earth," we focus on science education, human resource development, research and development, and the creation of new businesses. Work on a typical project. https://lne.st/